GLPwatch
Subcutaneous Semaglutide in Systemic Scleroderma
NCT06149260 · Unknown status
Last updated 2026-05-28This clinical trial is testing whether a medication called semaglutide, given as an injection under the skin, can help people with systemic scleroderma by measuring changes in skin thickness over 24 weeks.
Status Unknown status The sponsor has not confirmed the status recently.
Phase Phase 1 Checks safety and dosing in a small group.
Type Interventional (clinical trial)
Design open-label (no blinding) treatment study
Participants 10 people Planned (estimated).
Who can join Ages 18–65 · all sexes
Timeline Started 2024-02 · est. completion 2024-12
Where 1 site · China
What this study is testing ClinicalTrials.gov NCT06149260 ↗
Description as written by the study sponsor.
This trial will study the safety and efficacy of subcutaneous semaglutide for the treatment of Systemic Sclerosis
Treatments tested
- Semaglutide Pen Injector Drug
Inject semaglutide subcutaneously once weekly, on the same day each week, at any time of day, in a dose increasing mode: the initial dose of 0.25mg QW (once a week), increased to 0.5mg QW after 4 weeks, and then maintained 0.5mg until the end of treatment in total 24 weeks.
| Main thing measured | Change in modified Rodnan skin score (mRSS) at week 24 |
|---|---|
| Sponsor | Second Xiangya Hospital of Central South University |
| Conditions studied | Scleroderma, Systemic, Fibrosis, Semaglutide |
| GLP-1 drugs | semaglutide |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06149260 ↗